Ralph Niven, CHIEF SCIENTIFIC OFFICER at Aerovate Therapeutics, Inc. (AVTE), sold 2,250 shares at $16.22 ($35K) on 2022-10-05, disclosed to the SEC on 2022-10-07.
Scheduled sale ($35k) by CHIEF SCIENTIFIC OFFICER under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $15.71 | 2,059 | $32K | 91.3% |
| 2 | $16.22 | 191 | $3K | 8.7% |
| Total | $15.75 avg | 2,250 | $35K | 100% |
| Filing → |
| AVTE | SELL | 2023-12-07 | $75K | — | Filing → |
| AVTE | SELL | 2023-11-27 | $207K | — | Filing → |
| AVTE | SELL | 2023-07-07 | $39K | — | Filing → |